Linrodostat mesylate
Based on 7 publication(s) in Google Scholar
Linrodostat (BMS-986205) mesylate is a selective irreversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), which effectively inhibits IDO1-HEK293 mesylate cells with an IC50 value of 1.1 nM. Linrodostat mesylate demonstrates good pharmacological activity in advanced cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2221034-29-1
- 分子式: C25H28ClFN2O4S
- 分子量:507.02
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Linrodostat mesylate
More- Immunity. 2021 Oct 12;54(10):2354-2371.e8. [Abstract]
- Cell Death Differ. 2021 Feb;28(2):715-729. [Abstract]
- MedComm (2020). 2026 Mar 30;7(4):e70709. [Abstract]
- J Neuroinflammation. 2024 Nov 28;21(1):307. [Abstract]
- Cell Rep. 2024 Sep 13;43(9):114741. [Abstract]
- Heidelberg University. 2025.
- SSRN. 2023 Dec 1.
生物活性
|
IDO1 1.1 nM (IC50) |
化学情報
-
CAS 番号 2221034-29-1
-
分子量 507.02
-
分子式 C25H28ClFN2O4S
-
SMILES
O=C(NC1=CC=C(Cl)C=C1)[C@H](C)[C@@](CC2)([H])CC[C@H]2C3=CC=NC4=C3C=C(F)C=C4.OS(C)(=O)=O
-
別名
BMS-986205 mesylate; ONO-7701 mesylate
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. [Abstract]2021 Oct 12;54(10):2354-2371.e8. PMID: 34614413 -
Cell Death Differ
Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment. [Abstract]2021 Feb;28(2):715-729. PMID: 32929219 -
MedComm (2020)
Metabolic Alterations in Macrophage Subtypes Propel Immune and Stromal Remodeling in Neurofibroma's Malignant Progression. [Abstract]2026 Mar 30;7(4):e70709. PMID: 41930352 -
J Neuroinflammation
Taprenepag restores maternal-fetal interface homeostasis for the treatment of neurodevelopmental disorders. [Abstract]2024 Nov 28;21(1):307. PMID: 39609821 -
Cell Rep
Integrated metabolic-transcriptomic network identifies immunometabolic modulations in human macrophages. [Abstract]2024 Sep 13;43(9):114741. PMID: 39276347 -
-
純度とドキュメンテーション
参考文献
[1]. Richards T, et al. Cell based functional assays for IDO1 inhibitor screening and characterization. Oncotarget. 2018 Jul 20;9(56):30814-30820. [Content Brief]
[2]. Lillian L. Siu, et al. Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. AACR; Cancer Res. 2017; 77 (13 Suppl): Abstract nr CT116. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)